Literature DB >> 513610

[Haemodynamic studies on the blood pressure-raising effect of mineralocorticoids (author's transl)].

A Distler, T Philipp.   

Abstract

The effects on systemic haemodynamics of long-term administration of high mineralocorticoid doses were studied in six healthy volunteers. The subjects received the synthetic steroid fludrocortisone in a daily oral dose of 0.8 mg. Central venous and arterial pressures were recorded directly, and cardiac output was determined by dye dilution method before as well as after 1 and 6 weeks of steroid application. Within the first week of steroid administration, mean arterial pressure rose by 5.6 +/- 4.6 (+/- S.D.) mm Hg (p less than 0.025). Body weight increased by 2.5 +/- 1.1 kg (p less than 0.01), and central venous pressure by 1.3 +/- 1.4 mm Hg (p less than 0.05). An increase in cardiac index was observed in all subjects, the average increase was 0.72 +/- 0.47 1/min.m2 (p less than 0.01). Heart rate decreased. After the 6th week of steroid administration, blood pressure had risen in all subjects, the average increase in mean arterial pressure was 17.8 +/- 6.0 mm Hg (p less than 0.001). This pressure rise was the consequence of an increase in total peripheral resistance by 267 +/- 125 dyn.cm-5.s (p less than 0.01) on the average. At that time cardiac index was even lower than at the first study in five of the six subjects. Compared to the second study, heart rate had decreased further, central venous pressure had increased further, and body weight had not changed significantly. This data show that the mineralocorticoid-induced blood pressure rise is initially due to an increase in cardiac output and in its chronic phase due to an elevated peripheral resistance. The mechanism of the increase in peripheral resistance remains unclear.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 513610     DOI: 10.1007/bf01491758

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  35 in total

1.  Current status of the treatment of irenal disorders.

Authors:  G W THORN; D H NELSON; A E RENOLD
Journal:  J Am Med Assoc       Date:  1958-12-20

2.  Body fluid and electrolyte composition in arterial hypertension. II. Studies in mineralocorticoid hypertension.

Authors:  A V CHOBANIAN; B A BURROWS; W HOLLANDER
Journal:  J Clin Invest       Date:  1961-02       Impact factor: 14.808

3.  Tissue cations and water in arterial hypertension.

Authors:  L TOBIAN; J T BINION
Journal:  Circulation       Date:  1952-05       Impact factor: 29.690

4.  Hemodynamic characteristics of primary aldosteronism.

Authors:  R C Tarazi; M M Ibrahim; E L Bravo; H P Dustan
Journal:  N Engl J Med       Date:  1973-12-20       Impact factor: 91.245

5.  Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension.

Authors:  A C Guyton; T G Coleman; A V Cowley; K W Scheel; R D Manning; R A Norman
Journal:  Am J Med       Date:  1972-05       Impact factor: 4.965

6.  The effect of tyramine, noradrenaline, and angiotensin on the blood pressure in hypertensive patients with aldosteronism and low plasma renin.

Authors:  A Distler; C Barth; H Liebau; P Vecsei; H P Wolff
Journal:  Eur J Clin Invest       Date:  1970-11       Impact factor: 4.686

7.  The intercurrent hypertension of primary aldosteronism.

Authors:  E G Biglieri; M Schambelan; P E Slaton; J R Stockigt
Journal:  Circ Res       Date:  1970-07       Impact factor: 17.367

8.  Hypertension caused by salt loading in the dog. 3. Onset transients of cardiac output and other circulatory variables.

Authors:  T G Coleman; A C Guyton
Journal:  Circ Res       Date:  1969-08       Impact factor: 17.367

9.  Abnormalities of renal function and circulatory reflexes in primary aldosteronism.

Authors:  E G Biglieri; M B McIlroy
Journal:  Circulation       Date:  1966-01       Impact factor: 29.690

10.  Central and peripheral adrenergic mechanisms in the development of deoxycorticosterone-saline hypertension in rats.

Authors:  J L Reid; J A Zivin; I J Kopin
Journal:  Circ Res       Date:  1975-11       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.